Medicenna Extends Period to Exercise Certain Warrants

TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company (the “Warrants”) originally issued on October 17, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company (the “Common Shares”) at a price of $1.75 per Common Share and set to expire on July 17, 2023.

Read more at globenewswire.com